4.03

4.95% -0.21

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $4.03, with a volume of 1.05M. It is down -4.95% in the last 24 hours and down -19.40% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Previous Close:

$4.24

Open:

$4.25

24h Volume:

1.05M

Relative Volume:

1.12

Market Cap:

$243.66M

Revenue:

$217.78M

Net Income/Loss:

$-239.55M

P/E Ratio:

-0.9953

EPS:

-4.0492

Net Cash Flow:

$-127.30M

1W Performance:

-11.82%

1M Performance:

-19.40%

6M Performance:

-43.72%

1Y Performance:

-23.53%

1-Day Range:

$3.995

$4.27

1-Week Range:

$3.995

$4.56

52-Week Range:

$3.995

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

533

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	4.03	243.66M	217.78M	-239.55M	-127.30M	-4.0492
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-26	Initiated	Oppenheimer	Outperform
Mar-05-26	Initiated	Truist	Buy
Nov-05-25	Initiated	B. Riley Securities	Buy
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

Oct 15, 2026

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research

Oct 15, 2026

Oct 07, 2026

HC Wainwright reaffirms Buy for Vanda Pharmaceuticals stock - AD HOC NEWS

Oct 07, 2026

Oct 02, 2026

Three posters examine a treatment for a rare form of psoriasis - Stock Titan

Oct 02, 2026

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting - PR Newswire

Oct 02, 2026

Oct 01, 2026

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA) - Seeking Alpha

Oct 01, 2026

Sep 30, 2026

Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug - Benzinga

Sep 30, 2026

Sep 29, 2026

Vanda Pharmaceuticals says Phase III HETLIOZ study met sleep endpoint - Mugglehead Investment Magazine

Sep 29, 2026

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - Yahoo Finance

Sep 29, 2026

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PR Newswire

Sep 29, 2026

Sep 25, 2026

Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360

Sep 25, 2026

Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News

Sep 25, 2026

Sep 23, 2026

Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com

Sep 23, 2026

Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com India

Sep 23, 2026

Sep 11, 2026

VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView

Sep 11, 2026

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada

Sep 11, 2026

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com

Sep 11, 2026

VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView

Sep 11, 2026

Sep 04, 2026

DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz

Sep 04, 2026

Sep 02, 2026

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - PR Newswire

Sep 02, 2026

Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan

Sep 02, 2026

Aug 31, 2026